Targeted Therapies for Cancer: ImmunoGen, Inc.

Site Map

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Multiple compounds are in the clinic through our own programs and those of our partners.

Learn more about them...

We expect numerous presentations at medical meetings in the next few weeks.

See our presentations at AACR-NCI-EORTC...

11/19/2009
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology

11/17/2009
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma

Read our releases...

built@zoomedia.com

Last updated November 19, 2009